Oppenheimer analyst Hartaj Singh maintained a Buy rating on Pharming Group on Thursday, setting a price target of EUR2.5, which is approximately 99.82% above the present share price of 1.54.
Singh expects Pharming Group to post earnings per share (EPS) of 0.01 for the first quarter of 2021.
The current consensus among 0 TipRanks analysts is for a Hold rating of shares in Pharming Group, with an average price target of .
The analysts price targets range from a high of to a low of .
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of 46.12 million and a net profit of 18.83 million. The company's market cap is 1 billion.
According to TipRanks.com, Oppenheimer analyst Hartaj Singh is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.4% and a 44.71% success rate.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.